At my initial diagnosis I participated in a clinical trial evaluating Herceptin, a so-called personalized medicine (PM) drug targeting a mutation believed to be driving my cancer.
In the early 1990s DeVico figured he might get around the mutation problem by targeting the crucial portion of gp120 that is normally obscured by HIV's surface.